BR0014331A - Composto, inibidor de enzima sintetizadora de esqualeno, composição medicinal, processo para produção de um composto quinuclidìnico e processo para prevenção ou cura de uma doença - Google Patents
Composto, inibidor de enzima sintetizadora de esqualeno, composição medicinal, processo para produção de um composto quinuclidìnico e processo para prevenção ou cura de uma doençaInfo
- Publication number
- BR0014331A BR0014331A BR0014331-6A BR0014331A BR0014331A BR 0014331 A BR0014331 A BR 0014331A BR 0014331 A BR0014331 A BR 0014331A BR 0014331 A BR0014331 A BR 0014331A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- chain
- synthesizing enzyme
- optionally substituted
- disease
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 title abstract 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 title abstract 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 title abstract 3
- 229940031439 squalene Drugs 0.000 title abstract 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 title abstract 3
- 230000002194 synthesizing effect Effects 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 229940125532 enzyme inhibitor Drugs 0.000 title abstract 2
- 239000002532 enzyme inhibitor Substances 0.000 title abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- -1 QUINUCLIDINE COMPOUND Chemical class 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"COMPOSTO, INIBIDOR DE ENZIMA SINTETIZADORA DE ESQUALENO, COMPOSIçãO MEDICINAL, PROCESSO PARA A PRODUçãO DE UM COMPOSTO QUINUCLIDìNICO E PROCESSO PARA PREVENçãO OU CURA DE UMA DOENçA". A presente invenção proporciona um inibidor excelente para a enzima sintetizadora de esqualeno. Especificamente, ela apresenta um composto (I), representado por meio da fórmula que se segue, um de seus sais ou hidratos. Na qual R^ 1^ representa (1) um átomo de hidrogênio ou (2) um grupo hidroxila; HAr representa um heterociclo aromático que pode estar substituído com 1 a 3 grupos; Ar representa um anel aromático opcionalmente substituído; W significa uma cadeia representada por (1) -CH~ 2~CH~ 2~-, que pode estar substituída, (2) -CH=CH-, que pode estar substituída, (3) C<154>C-, (4) -NH-CO-, (5) -CO-NH-, (6) -NH-CH~ 2~-, (7) -CH~ 2~-NH-, (8) -CH~ 2~-CO-, (9) -CO-CH~ 2~-, (10) -NH-S(O)~ 1~-, (11) -S(O)~ 1~-NH-, (12) -CH~ 2~-S(O)~ 1~-, ou (13) -S(O)~ 1~-CH2-, (em que 1 representa 0, 1 ou 2); e X significa uma cadeia representada por meio de (1) uma ligação simples, (2) uma cadeia alquilênica C~ 1-6~, opcionalmente substituída, (3) uma cadeia alquenilênica C~ 2-6~, opcionalmente substituída, (4) uma cadeia alquinilênica C~ 2-6~,opcionalmente substuída, (5) uma fórmula -Q- (em que Q representa um átomo de oxigênio, um átomo de enxofre, CO ou N (R^ 2^ ) (em que R^ 2^ representa um grupo alquila C^ 1-6^ ou um grupo alcoxi C^ 1-6^, (6) -NH-CO-, (7) -CO-NH-, (8) -NH-CH^ 2^-, (9) -CH^ 2^-NH-, (10) -CH^ 2^-CO-, (11) -CO-CH~ 2~, (12) -NH-S(O)~ m~-, (13) -S(O)~ m~-NH-, (14) -CH~ 2~-S (O)~ m~-, (15) -S (O)~ m~-CH^ 2^-, (em que m representa 0, 1 ou 2) ou (16) - (CH~ 2~)~ n~-O- (em que n representa um inteiro de 1 a 6).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP27390599 | 1999-09-28 | ||
| JP2000179352 | 2000-06-15 | ||
| PCT/JP2000/006665 WO2001023383A1 (en) | 1999-09-28 | 2000-09-27 | Quinuclidine compounds and drugs containing the same as the active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0014331A true BR0014331A (pt) | 2003-06-10 |
Family
ID=26550809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0014331-6A BR0014331A (pt) | 1999-09-28 | 2000-09-27 | Composto, inibidor de enzima sintetizadora de esqualeno, composição medicinal, processo para produção de um composto quinuclidìnico e processo para prevenção ou cura de uma doença |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6599917B1 (pt) |
| EP (1) | EP1217001B1 (pt) |
| JP (1) | JP4206212B2 (pt) |
| KR (1) | KR100694687B1 (pt) |
| CN (1) | CN100334085C (pt) |
| AT (1) | ATE312100T1 (pt) |
| AU (1) | AU782114B2 (pt) |
| BR (1) | BR0014331A (pt) |
| CA (1) | CA2385995C (pt) |
| DE (1) | DE60024651T2 (pt) |
| DK (1) | DK1217001T3 (pt) |
| ES (1) | ES2252063T3 (pt) |
| HU (1) | HUP0203514A3 (pt) |
| IL (2) | IL148631A0 (pt) |
| MX (1) | MXPA02003167A (pt) |
| NO (1) | NO328218B1 (pt) |
| NZ (1) | NZ517788A (pt) |
| RU (1) | RU2266905C2 (pt) |
| TW (1) | TWI282794B (pt) |
| WO (1) | WO2001023383A1 (pt) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0010955D0 (en) * | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
| JP4225787B2 (ja) * | 2001-03-27 | 2009-02-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Ｎ−アリール環状アミン誘導体およびそれを有効成分として含有する医薬 |
| EP1256573A1 (en) | 2001-05-09 | 2002-11-13 | Eisai Co., Ltd. | Process for producing stereoisomer of pyrrolidine derivative |
| KR20050030169A (ko) * | 2001-10-17 | 2005-03-29 | 유씨비 소시에떼아노님 | 퀴누클리딘 유도체, 이의 제조 방법 및 ｍ2 및/또는 ｍ3무스카린 수용체 억제제로서의 이의 용도 |
| US7361671B2 (en) * | 2001-11-15 | 2008-04-22 | The Institute For Pharmaceutical Discovery, Inc. | Substituted heteroarylalkanoic acids |
| DE10225537A1 (de) * | 2002-06-10 | 2003-12-18 | Bayer Ag | N-alkylierte Thiazoliumsalze und Verfahren zu deren Herstellung |
| GB0218876D0 (en) * | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
| PL210065B1 (pl) | 2002-09-25 | 2011-11-30 | Memory Pharm Corp | Związki indazole, benzotiazole i benzoizotiazole, kompozycje farmaceutyczne je zawierające oraz zastosowanie związków |
| DE10334724A1 (de) * | 2003-07-30 | 2005-02-24 | Bayer Healthcare Ag | N-Biarylamide |
| WO2005046683A1 (en) * | 2003-10-07 | 2005-05-26 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| CA2560741C (en) | 2004-03-25 | 2013-08-06 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
| US8106066B2 (en) | 2005-09-23 | 2012-01-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| JP2010519328A (ja) | 2007-02-26 | 2010-06-03 | ファイザー・プロダクツ・インク | Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体およびプロスタグランジンｄ２が媒介する疾患の治療のためのそれらの使用 |
| TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| KR20130083389A (ko) | 2010-05-28 | 2013-07-22 | 바이오크리스트파마슈티컬즈,인코포레이티드 | 야누스 키나아제 억제제로서 헤테로사이클릭 화합물 |
| ES2790358T3 (es) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular |
| CA3142817A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
| WO2014060381A1 (de) | 2012-10-18 | 2014-04-24 | Bayer Cropscience Ag | Heterocyclische verbindungen als schädlingsbekämpfungsmittel |
| CN104884449A (zh) | 2012-10-31 | 2015-09-02 | 拜尔农作物科学股份公司 | 作为害虫防治剂的新的杂环化合物 |
| US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
| EP3919056B1 (en) | 2013-03-15 | 2024-08-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| CN112500338A (zh) | 2013-03-15 | 2021-03-16 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
| US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EP2968299B1 (en) | 2013-03-15 | 2021-01-20 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| SG10201911662YA (en) | 2014-02-07 | 2020-02-27 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
| JP6603334B2 (ja) | 2015-06-03 | 2019-11-06 | エフ．ホフマン−ラ ロシュ アーゲー | エチニル誘導体 |
| HUE072191T2 (hu) | 2015-12-04 | 2025-10-28 | Global Blood Therapeutics Inc | A 2-hidoxi-6-((2-(1-izopropil-1H-pirazol-5-il)piridin-3-il)metoxi)benzaldehid adagolási rendje |
| TWI825524B (zh) | 2016-05-12 | 2023-12-11 | 美商全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
| TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| CN112996795B (zh) | 2018-09-18 | 2024-11-12 | 尼坎治疗公司 | 作为src同源-2磷酸酶抑制剂的稠合的三环衍生物 |
| US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2105655A1 (en) * | 1991-03-08 | 1992-09-09 | Kent Neuenschwander | Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors |
| US5135935A (en) * | 1991-05-17 | 1992-08-04 | Merck & Co., Inc. | Squalene synthetase inhibitors |
| GB9127279D0 (en) * | 1991-12-23 | 1992-02-19 | Ici Plc | Heterocyclic derivatives |
| JPH05310732A (ja) * | 1992-03-12 | 1993-11-22 | Mitsubishi Kasei Corp | シンノリン−３−カルボン酸誘導体 |
| GB9207961D0 (en) * | 1992-04-10 | 1992-05-27 | Ici Plc | Heterocyclic derivatives |
| GB9218334D0 (en) * | 1992-08-28 | 1992-10-14 | Ici Plc | Heterocyclic compounds |
| AU7394394A (en) * | 1992-10-13 | 1995-12-05 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | 3-hydroxyquinuclidin-3-ylphenylquinolines as squalene synthase inhibitors |
| GB9226573D0 (en) | 1992-12-21 | 1993-02-17 | Ici Plc | Heterocyclic compounds |
| IL109451A0 (en) | 1993-04-29 | 1994-07-31 | Zeneca Ltd | Heterocyclic derivatives |
| GB9412145D0 (en) * | 1994-06-17 | 1994-08-10 | Zeneca Ltd | Heterocycles |
| JPH08134067A (ja) * | 1994-11-11 | 1996-05-28 | Yamanouchi Pharmaceut Co Ltd | キヌクリジン誘導体 |
| JPH08269056A (ja) * | 1995-03-29 | 1996-10-15 | Chugai Pharmaceut Co Ltd | スクアレンシンセターゼ阻害作用を有するキヌクリジン誘導体 |
| US5712270A (en) * | 1995-11-06 | 1998-01-27 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
| CA2254769A1 (en) * | 1996-05-20 | 1997-11-27 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
-
2000
- 2000-09-27 US US10/088,554 patent/US6599917B1/en not_active Expired - Fee Related
- 2000-09-27 WO PCT/JP2000/006665 patent/WO2001023383A1/ja not_active Ceased
- 2000-09-27 RU RU2002111344/04A patent/RU2266905C2/ru not_active IP Right Cessation
- 2000-09-27 MX MXPA02003167A patent/MXPA02003167A/es active IP Right Grant
- 2000-09-27 DE DE60024651T patent/DE60024651T2/de not_active Expired - Lifetime
- 2000-09-27 JP JP2001526535A patent/JP4206212B2/ja not_active Expired - Fee Related
- 2000-09-27 AU AU74464/00A patent/AU782114B2/en not_active Ceased
- 2000-09-27 TW TW089119958A patent/TWI282794B/zh not_active IP Right Cessation
- 2000-09-27 CA CA002385995A patent/CA2385995C/en not_active Expired - Fee Related
- 2000-09-27 AT AT00962889T patent/ATE312100T1/de not_active IP Right Cessation
- 2000-09-27 ES ES00962889T patent/ES2252063T3/es not_active Expired - Lifetime
- 2000-09-27 DK DK00962889T patent/DK1217001T3/da active
- 2000-09-27 KR KR1020027003952A patent/KR100694687B1/ko not_active Expired - Fee Related
- 2000-09-27 NZ NZ517788A patent/NZ517788A/en not_active IP Right Cessation
- 2000-09-27 IL IL14863100A patent/IL148631A0/xx unknown
- 2000-09-27 CN CNB00813541XA patent/CN100334085C/zh not_active Expired - Fee Related
- 2000-09-27 EP EP00962889A patent/EP1217001B1/en not_active Expired - Lifetime
- 2000-09-27 BR BR0014331-6A patent/BR0014331A/pt not_active Application Discontinuation
- 2000-09-27 HU HU0203514A patent/HUP0203514A3/hu unknown
-
2002
- 2002-03-12 IL IL148631A patent/IL148631A/en not_active IP Right Cessation
- 2002-03-26 NO NO20021528A patent/NO328218B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1217001B1 (en) | 2005-12-07 |
| CN1377349A (zh) | 2002-10-30 |
| IL148631A0 (en) | 2002-09-12 |
| DE60024651T2 (de) | 2006-09-28 |
| CN100334085C (zh) | 2007-08-29 |
| NO328218B1 (no) | 2010-01-11 |
| NZ517788A (en) | 2003-11-28 |
| HUP0203514A3 (en) | 2004-01-28 |
| JP4206212B2 (ja) | 2009-01-07 |
| KR100694687B1 (ko) | 2007-03-13 |
| IL148631A (en) | 2010-04-29 |
| EP1217001A1 (en) | 2002-06-26 |
| EP1217001A4 (en) | 2002-12-18 |
| NO20021528D0 (no) | 2002-03-26 |
| TWI282794B (en) | 2007-06-21 |
| US6599917B1 (en) | 2003-07-29 |
| ATE312100T1 (de) | 2005-12-15 |
| NO20021528L (no) | 2002-05-28 |
| KR20020034197A (ko) | 2002-05-08 |
| AU782114B2 (en) | 2005-07-07 |
| ES2252063T3 (es) | 2006-05-16 |
| HUP0203514A2 (hu) | 2003-03-28 |
| MXPA02003167A (es) | 2003-10-06 |
| WO2001023383A1 (en) | 2001-04-05 |
| DE60024651D1 (de) | 2006-01-12 |
| CA2385995C (en) | 2009-06-16 |
| AU7446400A (en) | 2001-04-30 |
| RU2266905C2 (ru) | 2005-12-27 |
| DK1217001T3 (da) | 2006-03-20 |
| CA2385995A1 (en) | 2001-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0014331A (pt) | Composto, inibidor de enzima sintetizadora de esqualeno, composição medicinal, processo para produção de um composto quinuclidìnico e processo para prevenção ou cura de uma doença | |
| BR0114436A (pt) | Composto com anel de cinco elementos contendo nitrogênio alifático | |
| BRPI0417687A (pt) | derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade | |
| BR0316991A (pt) | Compostos de anel de 1,3-diidro-imidazol fundido | |
| BRPI0514644A (pt) | composto fosforamidita, composto ácido ribonucléico, e método para produzir oligo-rna | |
| ES2127722T3 (es) | Aralquilaminas, procedimiento para su preparacion y composiciones farmaceuticas que las contienen. | |
| BR112012007069A2 (pt) | derivado de fenol | |
| BR9812095A (pt) | Compostos de indol como inibidores de cox-2 | |
| BR9813835A (pt) | Composto, composição farmacêutica e método de tratamento ou prevenção de uma desordem tromboembólica | |
| BR0212378A (pt) | Inibidores de 17beta-hidroxiesteróide desidrogenase tipo 3 para o tratamento de doenças dependentes de androgênio | |
| BRPI0407283A (pt) | Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade | |
| BRPI0511186A (pt) | composto, pró-droga do composto, composição farmacêutica, uso do composto, e, processo para preparar o composto | |
| BR0010555A (pt) | Inibidores de neuraminidases | |
| BR0314133A (pt) | Métodos para a preparação, isolamento e purificação de epotilona b e raios x de estruturas de cristal de epotilona b | |
| BR9712134A (pt) | cidos hiidroxâmicos de b-sulfonila como inibidores de metaloproeinases de matriz. | |
| BRPI0408338A (pt) | piperidinas substituìdas como novos inibidores de mdm2-p53 | |
| UY25114A1 (es) | Derivados orto-sustituidos de la hidroxicumaranona como agentes antitumorales y antimetastásicos. | |
| BR0312798A (pt) | Derivados de isotiazol úteis como agentes anticancerìgenos | |
| BR0307801A (pt) | Processo para a fabricação de derivados de ácido mevalÈnico inibidores da hmg-coa reductase | |
| AR025103A1 (es) | Quelantes quimicos para la reversion del bloqueo neuromuscular inducido por farmacos | |
| BRPI0406500A (pt) | processo farmacêutico e compostos preparados pelo mesmo | |
| BR0311410A (pt) | Composto de piperidina | |
| BR0310033A (pt) | Inibidores da transcriptase reversa de não-nucleosìdeo | |
| BRPI0411308A8 (pt) | Composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto | |
| BR0014615A (pt) | Derivado de ácido fosfÈnico que apresenta atividade inibidora contra carboxipeptidase b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: EISAI R AND D MANAGEMENT CO., LTD. (JP) Free format text: TRANSFERIDO DE: EISAI CO., LTD. |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 24 E 25 DA LPI. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |
|
| B15K | Others concerning applications: alteration of classification |
Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: C07D 453/02; A61K 31/4545; A61K 31/444; A61K 31/506; A61K 31/439; A61P 43/00; A61P 3/06; A61P 9/10; C07M 7/00. Ipc: C07D 453/02 (2006.01) Ipc: C07D 453/02 (2006.01) |